Yahoo · Oct 2, 2026
GeneDx Introduces Easy Order at AAP 2026 to Simplify Genomic Testing in Everyday Pediatric Care
GAITHERSBURG, Md., October 02, 2026--GeneDx introduces Easy Order at AAP 2026 to simplify genomic testing in everyday pediatric care
WG
NASDAQ · WGS
GeneDx Holdings Corp.
Healthcare · Medical - Healthcare Information Services
$76.27
Down-$4.75 (-6.23%)
Updated Oct 7, 2026, 12:17 AM
SID Score
4.0/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 4.49B
- P/E ratio
- 2,147.87
- Dividend yield
- 0.00%
- 52-week range
- $32.21 – $105.18
- Volume
- 855.22K
- Avg. volume
- 519.06K
Price performance · WGS
WGS price history
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 5, 2026
WGS closed at $76.27 after 20 trading sessions, down 11.18% for the selected period.
- Last close
- $76.27
- Period change
- -11.18%
- Period low
- $70.96
- Period high
- $104.95
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 5, 2026 | $73.35 | $77.20 | $72.04 | $76.27 | 855.22K |
| Oct 2, 2026 | $71.13 | $74.86 | $70.4825 | $73.09 | 606.7K |
| Oct 1, 2026 | $72.77 | $75.49 | $70.69 | $70.96 | 858.03K |
| Sep 30, 2026 | $75.74 | $75.81 | $72.11 | $72.30 | 905.17K |
| Sep 29, 2026 | $85.59 | $87.86 | $74.16 | $75.79 | 1.33M |
| Sep 28, 2026 | $87.33 | $89.32 | $84.90 | $85.93 | 437.03K |
| Sep 25, 2026 | $89.00 | $90.99 | $86.135 | $88.40 | 510.36K |
| Sep 24, 2026 | $84.46 | $93.51 | $83.10 | $88.48 | 1.55M |
| Sep 23, 2026 | $90.50 | $92.8096 | $84.35 | $85.20 | 1.05M |
| Sep 22, 2026 | $95.19 | $95.19 | $87.33 | $90.80 | 1.69M |
| Sep 21, 2026 | $101.30 | $102.21 | $97.14 | $97.83 | 734.22K |
| Sep 18, 2026 | $104.59 | $105.00 | $99.7001 | $101.10 | 786.14K |
| Sep 17, 2026 | $99.61 | $105.18 | $98.39 | $104.95 | 827.27K |
| Sep 16, 2026 | $94.23 | $99.86 | $94.23 | $97.42 | 791.99K |
| Sep 15, 2026 | $88.81 | $97.7299 | $88.81 | $94.64 | 833.79K |
| Sep 14, 2026 | $85.64 | $90.17 | $83.875 | $89.74 | 517.78K |
| Sep 11, 2026 | $85.17 | $87.62 | $84.355 | $85.265 | 331.6K |
| Sep 10, 2026 | $83.85 | $87.1346 | $82.00 | $83.96 | 711.68K |
| Sep 9, 2026 | $84.22 | $88.84 | $84.00 | $86.48 | 493.1K |
| Sep 8, 2026 | $85.31 | $86.57 | $83.00 | $85.87 | 426.65K |
Latest WGS news
The latest Smart Investors Daily articles mentioning WGS.
Stock researchCompany · Overview
Company
Market Activity
Research & News
WGS research
Overview
Company profile and research snapshot.
Company profile
GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. The company is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $153.75
- Implied upside
- —
- Analysts
- 13
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 1, 2026 | Guggenheim | Buy | — |
| Aug 4, 2026 | Canaccord Genuity | Buy | — |
| Aug 4, 2026 | BTIG | Buy | — |
| Jun 29, 2026 | Guggenheim | Buy | — |
| Jun 23, 2026 | Piper Sandler | Overweight | — |
News briefing
No generated briefing is available yet.
Benzinga · Oct 1, 2026
Guggenheim Maintains Buy on GeneDx Holdings, Raises Price Target to $83
Guggenheim analyst Subbu Nambi maintains GeneDx Holdings (NASDAQ:WGS) with a Buy and raises the price target from $74 to $83.
Yahoo · Sep 24, 2026
GeneDx Stock Is Down 30% In Last 1 Year, Can It Climb Again in 2027?
Key Takeaways:Record Testing Volume: GeneDx delivered over 30,000 exome and genome tests in Q2, up 32% year-over-year, and returned to profitability a quarter ahead of schedule. Price Projection: Based on current assumptions, WGS stock could reach $137 by December 2028.
Yahoo · Sep 9, 2026
GeneDx and Beren Therapeutics Launch NPC GenomeComplete to Improve Diagnosis of Niemann-Pick Disease Type C
GAITHERSBURG, Md., September 09, 2026--GeneDx and Beren Therapeutics Launch NPC GenomeComplete to Improve Diagnosis of Niemann-Pick Disease Type C
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
